Document Detail

Polymorphisms of the angiotensinogen gene and the outcome of microalbuminuria in essential hypertension: a 3-year follow-up study.
MedLine Citation:
PMID:  14688807     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: The objective of this study was to analyse the relationship of polymorphisms of the angiotensinogen (AGT) gene with the changes in microalbuminuria during 3 years of antihypertensive treatment in a group of young adults with essential hypertension. METHODS: Essential hypertensives, less than 50 years old, never previously treated with antihypertensive drugs and in the absence of diabetes mellitus were included. After the initial evaluation, patients were treated using only nonpharmacological measures (n=23), only beta-blockers (n=26), only angiotensin-converting enzyme inhibitors (ACEi) (n=57) or a combination of treatments (n=25). The office blood pressure, biochemical profile and urinary albumin excretion (UAE) were measured at the beginning and then yearly. The polymorphism A-6G of the AGT gene located in the promoter region was analysed. RESULTS: In total, 131 patients, 35 (27%) microalbuminurics, were included. Although no significant differences in systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting glucose and UAE were observed among genotypes at the initial examination, during the 3 years of antihypertensive treatment the slope values for the DBP, fasting glucose and UAE differed significantly despite no differences in the distribution of treatments being present. The subjects carrying the AA-6 genotype had the largest DBP decrease, but the lowest UAE reduction and the highest slope of glucose. Out of 35 initially microalbuminuric patients, 24 became normoalbuminuric and the lowest reduction rates were observed in subjects who carried the allele A-6. No interaction between the type of treatment and genotype was observed on the changes in UAE, BP or glucose values. In the subset of 57 patients treated with ACEi, the changes in UAE, BP and glucose had the same trend as was observed in the total population. CONCLUSIONS: Subjects carrying the AA genotype of the A-6G AGT gene polymorphism are resistant to a reduction of microalbuminuria. Whether this can be attributed to a predisposition to glucose metabolic disturbance or not needs to be confirmed in further studies.
P Marin; R Julve; F J Chaves; V Giner; J M Pascual; M E Armengod; J Redon
Related Documents :
21602937 - Insulin versus an oral antidiabetic agent as add-on therapy in type 2 diabetes after fa...
22170707 - Insulin sensitivity and β-cell function in adults with lifetime, untreated isolated gro...
18617287 - The association of the pax4 gene with type 1 diabetes in han chinese.
15988697 - Serum glucose concentration and acp1 genotype in healthy adult subjects.
11597987 - Prostaglandin h synthase and vascular function.
7016847 - Effect of amino acids on insulin-stimulated glucose metabolism in fat cells.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of human hypertension     Volume:  18     ISSN:  0950-9240     ISO Abbreviation:  J Hum Hypertens     Publication Date:  2004 Jan 
Date Detail:
Created Date:  2003-12-22     Completed Date:  2004-11-03     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8811625     Medline TA:  J Hum Hypertens     Country:  England    
Other Details:
Languages:  eng     Pagination:  25-31     Citation Subset:  IM    
Copyright Information:
Journal of Human Hypertension (2004) 18, 25-31. doi:10.1038/sj.jhh.1001630
Instituto Investigaciones Citológicas, Fundación Valenciana de Investigaciones Biomédicas, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic beta-Antagonists / therapeutic use*
Albuminuria / drug therapy,  urine
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Angiotensinogen / genetics*
Antihypertensive Agents / therapeutic use*
Blood Glucose / analysis
Blood Pressure
Follow-Up Studies
Hypertension / drug therapy,  genetics*,  urine
Polymorphism, Genetic
Time Factors
Treatment Outcome
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Blood Glucose; 11002-13-4/Angiotensinogen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Diagnostic value of carotid intima-media thickness and plaque score for predicting target organ dama...
Next Document:  Electrocardiographic assessment of left ventricular hypertrophy with time-voltage QRS and QRST-wave ...